Syntara drug candidate slows motor decline in people at high risk of Parkinson's
A Phase 2 clinical trial shows that Syntara's drug candidate SNT-4728 improved motor function in patients at high risk of developing Parkinson's disease. The drug, which targets brain inflammation, showed lasting benefits even after treatment concluded.
Why it matters
This development offers a potential breakthrough in treating neurodegenerative conditions by addressing symptoms before full-scale Parkinson's disease onset.
An experimental treatment being developed by Syntara improved movement in people at high risk of developing Parkinson's disease, and the benefit held for three months after treatment stopped, according to new results from a Phase 2 trial.
Syntara has announced that participants with isolated REM sleep behaviour disorder (iRBD) who took SNT-4728 showed a statistically significant difference in clinician-assessed motor signs compared with placebo at week 24. That point came 12 weeks after treatment ended.
iRBD is a sleep disorder associated with a high risk of progression to Parkinson's disease and related synucleinopathies.
Principal investigator Professor Simon Lewis of the Macquarie University Brain Institute and Clinic is presenting the findings today at the Clinical Breakthroughs Plenary Session of the International Congress of Parkinson's Disease and Movement Disorders in Seoul.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in